Sai Life Sciences upgraded to IND AA by India Ratings on bank loans
- Credit rating
- Pharmaceutical CRO/CDMO

Sai Life Sciences (NSE: SAILIFE) had the long-term rating on its bank loan facilities upgraded to 'IND AA' from 'IND AA-' by India Ratings, with a Stable Outlook and the short-term rating affirmed at 'IND A1+', it said in a filing on 13 Nov 2026. The rated facilities total ₹769 crore.
Key highlights
- Rated bank loan facilities: ₹769 crore
- Long-term rating: IND AA, Stable Outlook (from IND AA-)
- Short-term rating: IND A1+ affirmed
- Negative trigger: net leverage sustained above 1.5x
The rating action in numbers
| Item | Detail |
|---|---|
| Instrument | Bank loan facilities |
| Amount rated | ₹769 crore (INR 7,690 million) |
| Long-term rating | IND AA, Stable Outlook, upgraded from IND AA- |
| Short-term rating | IND A1+, affirmed |
| Rating agency | India Ratings & Research |
| Planned capex FY27 | ₹1,100 crore to ₹1,300 crore |
| Net leverage trigger | Consolidated net leverage above 1.5x, sustained |
A one-notch upgrade on a ₹769 crore facility
India Ratings has upgraded the long-term rating on Sai Life Sciences' bank loan facilities to 'IND AA' from 'IND AA-' and affirmed the short-term rating at 'IND A1+'. The rated limit is ₹769 crore. India Ratings says the upgrade reflects its expectation of sustained improvement in the business and financial profile, supported by growth across the CRO and CDMO businesses, stronger operating profitability and comfortable credit metrics.
Consolidated revenue was ₹2,192.50 crore in FY26 and ₹1,212.90 crore in 1HFY27, with EBITDA of ₹631.20 crore and ₹334.40 crore. EBITDA margin was 28.8% in FY26 and 27.6% in 1HFY27, per India Ratings. Blacklitt's data shows Q2 FY27 consolidated net profit of ₹98.32 crore, up 17.3% year on year.
Capex and leverage are the main watch points
India Ratings says capex of ₹1,100 crore to ₹1,300 crore planned in FY27 is likely to keep net leverage elevated relative to current levels and return ratios subdued over the medium term. It names the timely commissioning and ramp-up of new capacity as key monitorables.
India Ratings says a negative rating action could follow if consolidated net leverage is sustained above 1.5x. The company availed ₹70 crore of term debt in 1HFY27 and is likely to raise more borrowings in 2HFY27, according to the agency.
What the rating upgrade means for Sai Life Sciences shareholders
No dated step beyond the rating action itself appears in the filing.
Filed with BSE on . Reference: Original filing (PDF)
Disclaimer:
The information available on this article is provided for education and informational purposes only. It does not constitute or provide financial, investment or trading advice and should not be construed as an endorsement of any specific stock or financial strategy in any form or manner. We do not make any representations or warranties regarding the quality, reliability, or accuracy of the information provided. This website may contain links to third-party content. We are not responsible for the content or accuracy of these external sources and do not endorse or verify the information provided by third parties. We are not liable for any decisions made or actions taken based on the information provided on this website.